Chinese vaccine makers jump on news of key success in cancer treatment, CanSino leads

Genscript Biotech

20/08/2026 09:02

** Hong Kong shares of CanSino Biologics 6185.HK soar as much as 71.4% to HK$40, their highest point since January 2, leading rally in HK-listed Chinese vaccine makers
** Shanghai shares of the human vaccine producer 688185.SS jump 20% to their highest level since May 25
** Healthcare stocks surged in both China and Hong Kong after Moderna MRNA.O and Merck MRK.N on Wednesday announced a major success in a new field of cancer treatment that sent Moderna's shares surging as much as 160%, while Merck jumped 12%
** HK-listed Genscript Biotech Corp 1548.HK jump nearly 20% to HK$35.22, the highest level since December 2021
** Sino Biopharmaceutical 1177.HK jumps as much as 21.2% to HK$5.805, the highest since May 12
** Akeso Inc 9926.HK, Innovent Biologics 1801.HK, WuXi Biologics 2269.HK up between 3.1% and 5.7% 
** Hong Kong's Hang Seng Innovative Drug Index .HSIDI surges 4.7%, Hang Seng Biotech Index HSBIO up 4.5%
** China's CSI Vaccine and Biotech Index .CSI931992 jumps 9.2%

(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))